Petroianu Georg A, Maleck Wolfgang H, Koetter Katharina P, Liu Jie, Schmitt Andrea
Department of Pharmacology, United Arab Emirates University, Al Ain.
Crit Care Med. 2003 Jan;31(1):250-4. doi: 10.1097/00003246-200301000-00039.
A recent thrombelastography study indicated a compromised in vitro blood coagulation after 10:10 (equal parts of blood and infusion) and 10:4 (10 parts blood to four parts infusion) hemodilution with several plasma substitutes. Oncovertin N (Oncovertin) (a 10% dextran 40 solution) had the strongest anticoagulant effect of all solutions tested, and HAES-sterile 10% (HAES) (a 10% hydroxyethyl starch 200/0.5 solution) showed the strongest effect of five different hydroxyethyl starch preparations. The aim of this study was to determine how in vitro hemodilution with HAES and Oncovertin affects the activity of coagulation factors.
HAES and Oncovertin were tested to determine the intrinsic effect of colloid molecules, as opposed to hemodilution. Normal saline (NaCl) and nonlactated Ringer solution were used as noncolloidal controls.
University research institute.
Six healthy volunteers.
Twenty milliliters of blood was obtained from each subject.
Prothrombin index, activated partial prothrombin time, soluble fibrin monomers, and the activity of coagulation factors I, II, V, VII, VIII, IX, X, XI, and XII were measured with the Behring Chromotimer according to the manufacturer's instructions. Two dilution ratios of citrated blood to infusion were used: 10:10 (equal parts of blood and infusion) and 10:4 (10 parts blood to four parts infusion). Baseline was undiluted. Hemodilution with NaCl at both 10:4 and 10:10 influenced the coagulation variables measured. The activities of factors I, VII, and soluble fibrin monomers were less influenced than expected by hemodilution alone. The activities of factors II, V, IX, and XI were significantly (p <.04) lower with both 10:4 and 10:10 dilution with NaCl. In the assays for factors IX, XI, and XII, clots formed immediately after adding the appropriate reagents in the presence of Ringer solution at 10:10 hemodilution, so that the activities of those factors could not be measured. For the other factors and for 10:4 dilution, the outcome after Ringer solution was similar to that of NaCl. The activities were less influenced after 10:4 hemodilution with both HAES and Oncovertin than after dilution with NaCl and Ringer solution, with no significant differences from baseline. At 10:10 hemodilution with both HAES and Oncovertin, several factor activities were significantly (p <.04) lower than baseline.
Both NaCl and Ringer solution cause measurable effects on coagulation factors at 10:4 hemodilution that can be explained by hemodilution alone. The effects on clotting factors of 10:4 hemodilution with HAES and Oncovertin were not significant. Even at 10:10 hemodilution with HAES or Oncovertin, the reduction in factor activities, although significantly (p <.04) different from baseline, was less than what was expected by dilution alone.
最近一项血栓弹力图研究表明,使用几种血浆代用品进行10:10(血液与输注液等量)和10:4(10份血液对4份输注液)血液稀释后,体外血液凝固功能受损。在所有测试溶液中,昂可维丁N(Oncovertin)(一种10%的右旋糖酐40溶液)具有最强的抗凝作用,而贺斯无菌10%(HAES)(一种10%的羟乙基淀粉200/0.5溶液)在五种不同的羟乙基淀粉制剂中表现出最强的作用。本研究的目的是确定用HAES和昂可维丁进行体外血液稀释如何影响凝血因子的活性。
测试HAES和昂可维丁以确定胶体分子的内在作用,与血液稀释作用相对。生理盐水(NaCl)和非乳酸林格溶液用作非胶体对照。
大学研究机构。
六名健康志愿者。
从每位受试者采集20毫升血液。
根据制造商的说明,使用贝林色度计测量凝血酶原指数、活化部分凝血活酶时间、可溶性纤维蛋白单体以及凝血因子I、II、V、VII、VIII、IX、X、XI和XII的活性。使用两种枸橼酸盐血液与输注液的稀释比例:10:10(血液与输注液等量)和10:4(10份血液对4份输注液)。基线为未稀释状态。10:4和10:10的NaCl血液稀释均影响所测量的凝血变量。因子I、VII和可溶性纤维蛋白单体的活性受血液稀释的影响小于预期。10:4和10:10的NaCl稀释时,因子II、V IX和XI的活性显著(p<.0)降低。在因子IX、XI和XII的检测中,在10:10血液稀释且存在林格溶液的情况下,加入适当试剂后立即形成凝块,因此这些因子的活性无法测量。对于其他因子和10:4稀释,林格溶液后的结果与NaCl相似。与用NaCl和林格溶液稀释相比,用HAES和昂可维丁进行10:4血液稀释后活性受影响较小,与基线无显著差异。在用HAES和昂可维丁进行10:10血液稀释时,几种因子活性显著(p<.04)低于基线。
NaCl和林格溶液在10:4血液稀释时对凝血因子有可测量的影响,这仅用血液稀释即可解释。用HAES和昂可维丁进行10:4血液稀释对凝血因子的影响不显著。即使在用HAES或昂可维丁进行10:10血液稀释时,因子活性的降低虽然与基线有显著(p<.04)差异,但小于仅由稀释所预期的程度。